EUVIMEDEUVIMED entdecken
Crossref

Longitudinal Dynamics of Polyglutamine‐Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3

Jordan Bartfield, Lukasz Milanowski, Karen R Jansen-West, Rana Hanna Al-Shaikh, Tomasz Chmiela iD, Tania F Gendron, Judith A Dunmore iD, Sorina Gorcenco iD, Andreas Puschmann, João Lemos, Cristina Januário, Mark S LeDoux und 15 weitere

Movement Disorders · 2026

DOI: 10.1002/mds.70411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2026. Verfasst von Jordan Bartfield und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Machado-Joseph Disease, Ataxin-3, Peptides, Repressor Proteins. Die Arbeit nennt 23 Literaturangaben. Gefördert von: NIH HHS, Haworth Family Professorship, Donald G. and Jodi P. Heeringa Family.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Spinocerebellar ataxia type 3 (SCA3), the most common autosomal dominant ataxia, is driven by the accumulation of polyglutamine‐expanded (polyQ) ATXN3 proteins. While promising as biomarkers, their longitudinal trajectories across multiple biofluids remain poorly defined.

Objectives

To quantify polyQ ATXN3 levels in cerebrospinal fluid (CSF), plasma, and urine within a comprehensive cohort, utilizing serial measurements to map protein dynamics.

Methods

We employed a validated immunoassay to quantify polyQ ATXN3 in 97 symptomatic and 13 presymptomatic SCA3 patients, correlating levels with clinical features, ancestry, disease status, and longitudinal progression.

Results

Asian participants exhibited lower plasma but elevated urinary polyQ ATXN3 levels relative to other ancestries. While CSF levels were higher in symptomatic patients at baseline, they showed a significant longitudinal decline.

Conclusions

PolyQ ATXN3 is a viable multi‐biofluid biomarker. Declining CSF levels likely reflect neurodegeneration, supporting its role in tracking progression and emphasizing the need for ancestry‐based adjustment in trials. © 2026 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Machado-Joseph DiseaseAtaxin-3PeptidesRepressor ProteinsHumansFemaleMaleMiddle AgedLongitudinal StudiesAdultBiomarkersDisease ProgressionAged

Stichwörter der Autor:innen

CSFSCA3longitudinal dynamicsplasmapolyQ ATXN3urine

Substanzen

Ataxin-3PeptidesATXN3 protein, humanpolyglutamineRepressor ProteinsBiomarkers

Autor:innen und Institutionen

  • Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Neurology, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland.
  • Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA.
  • Department of Neurology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland.
  • Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden.

ORCID-Profile: Tomasz Chmiela, Judith A Dunmore, Sorina Gorcenco, Joseph H Friedman, Jaroslaw Slawek, Zbigniew K Wszolek

Förderung

  • NIH HHS
  • Haworth Family Professorship
  • Donald G. and Jodi P. Heeringa Family
  • Val Shapiro & Jordan Russell Family and Houlihan Lokey, Inc.
  • The Albertson Parkinson's Research Foundation,
  • PPND Family Foundation
  • Target ALS
  • BrightFocus Foundation

Zitieren

APA

Bartfield, J., Milanowski, L., Jansen-West, K. R., Hanna Al-Shaikh, R., Chmiela, T., Gendron, T. F., Dunmore, J. A., Gorcenco, S., Puschmann, A., Lemos, J., Januário, C., LeDoux, M. S., Friedman, J. H., Onodera, O., Aiba, I., Pfeiffer, R. F., Paulson, H. L., McLoughlin, H. S., Dulski, J., …, & Wszolek, Z. K. (2026). Longitudinal Dynamics of Polyglutamine‐Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3. Movement Disorders. https://doi.org/10.1002/mds.70411

Vancouver

Bartfield J, Milanowski L, Jansen-West KR, Hanna Al-Shaikh R, Chmiela T, Gendron TF, et al. Longitudinal Dynamics of Polyglutamine‐Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3. Movement Disorders. 2026. doi:10.1002/mds.70411

BibTeX
@article{Bartfield2026,
  author = {Bartfield, Jordan and Milanowski, Lukasz and Jansen-West, Karen R and Hanna Al-Shaikh, Rana and Chmiela, Tomasz and Gendron, Tania F and Dunmore, Judith A and Gorcenco, Sorina and Puschmann, Andreas and Lemos, João and Januário, Cristina and LeDoux, Mark S and Friedman, Joseph H and Onodera, Osamu and Aiba, Ikuko and Pfeiffer, Ronald F and Paulson, Henry L and McLoughlin, Hayley S and Dulski, Jaroslaw and Slawek, Jaroslaw and Teive, Helio A G and Soto-Piña, Alexandra E and Uitti, Ryan J and Strongosky, Audrey and Petrucelli, Leonard and Prudencio, Mercedes and Wszolek, Zbigniew K},
  title = {Longitudinal Dynamics of Polyglutamine‐Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70411}
}
Kostenlos starten →